Abstract 1503: Anticancer effects of a nutrient mixture in human melanoma cells A2058: Inhibition of cell proliferation, MMP expression, invasion and apoptosis

Abstract Introduction: Melanoma, an extremely aggressive cancer, causes the majority of skin cancer-related deaths, secondary to metastasis to other organs of the body, such as lymph nodes, lungs, liver, brain or bone. Currently, there are no viable treatments for melanoma. We investigated the effect of a specific mixture (PB) of quercetin, cruciferex, curcumin, green tea extract and resveratrol on human melanoma cell line A2058 for viability, MMP expression, invasion, apoptosis and cell morphology. Materials and Methods: Melanoma cells A2058 (ATCC), were maintained in DMEM culture, supplemented with 10% FBS and antibiotics in 24-well tissue plates. At near confluence, cells were treated with PB at 0, 10, 25, 50, 75 and 100 mcg/mL concentration in triplicate at each dose. Cells were also treated with PMA (100 ng/mL) for MMP-9 induction. Cell proliferation was assessed by MTT assay, MMPs by zymography, invasion through Matrigel, apoptosis using green caspase detection, and morphology by H&E staining. Results: PB inhibited proliferation of melanoma cells A2058 by 45% at 10 mcg/mL and 80% at 25-100 mcg/mL concentration, and inhibited the secretion of both MMP-2 and MMP-9 in a dose dependent manner with total inhibition at 50 mcg/mL concentration. Invasion through Matrigel was inhibited by 65% at 10 mcg/mL and 100% at 25 mcg/mL, respectively. PB also induced apoptosis in a dose-dependent fashion. H&E staining showed slight morphological changes at higher concentrations. Conclusions: In conclusion, PB significantly inhibited melanoma cell growth, invasion through Matrigel, MMP-2 and -9 expression and apoptosis, important parameters for cancer prevention, suggesting PB as a potential effective treatment of melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1503. doi:10.1158/1538-7445.AM2011-1503